CTSO Cytosorbents Corp

$CTSO Don’t see any real catalysts to drive this share price higher prior to the November earnings call. However, if they start tapping the ATM, it’ll likely start driving the share price down.

$CTSO R/S-ing into oblivion. FDA is moribund, and therefore will Kafkaesque-sleepwalk through a fog of its own making while company attempts to claw its way out of a misplaced bet on German medical reticence. This, and general EU confounders will yield a company in R&D, marketing, and revenue stasis that will persist into next offering and subsequent R/S.

$CTSO I firmly believe that the only successful investment strategy for CTSO during the remainder of the calendar year involves selling short. However, the current low number of outstanding shares (approximately 3 million) will make it difficult to access shares to sell short. However, if the Company issues and sells new shares to raise capital, accessing shares to short should become easier. Time will tell.

$CTSO ouch, who would buy this after yet another reverse? Seems like all they can sell is stock.

$CTSO Now that the 20:1 reverse stock split has been announced to take place on Sept 8, I anticipate we we will see a forthcoming announcement prior to the end of the calendar year announcing a dilutive issuance of additional shares to provide the Company with additional working capital. In addition, I expect short sellers will aggressively move in after the reverse split given their anticipation of a future dilutive financing round. Hope I’m wrong, but I doubt it.

$CTSO ATM won't cut it; the first shoe has dropped; the second shoe is a financing, CEO has actually said as much. Once that's completed, this will look interesting.

$CTSO CytoSorbents Announces 1 for 20 Reverse Stock Split https://www.prnewswire.com/news-releases/cytosorbents-announces-reverse-stock-split-302868315.html Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026.

$CTSO is seeing a strong reaction on clinical trial results following a PR Newswire release. CytoSorbents announces real-world data showing 37% reduction in severe bleeding with CytoSorb in CABG patients on ticagrelor, supporting FDA De Novo submission for DrugSorb-ATR. RTPR pushed this release out to users at 7:29:18 AM ET

$CTSO CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

$CTSO If you can wait for both shoes to drop, I suspect there may be a compelling entry point ahead...